Mild mesangial proliferative IgA nephropathy with and without minimal change disease.
Wang S, Huang B, Wang P, Liu Y, Liu Y, Chen H, Zhang J.
Clin Exp Med. 2023 Dec;23(8):5367-5376. doi: 10.1007/s10238-023-01184-0. Epub 2023 Oct 5.
Steroid-sensitive recurrent mesangial proliferative glomerulonephritis with monoclonal IgG deposits.
Nomura K, Miyatake N, Okada K, Hayashi N, Fujimoto K, Adachi H, Furuichi K, Shimizu A, Yokoyama H.
CEN Case Rep. 2021 May;10(2):308-313. doi: 10.1007/s13730-020-00562-x. Epub 2021 Jan 4.
Mesangial proliferative glomerulonephritis. Natural history and effects of dextran sulfate.
Dohi K, Nakamoto Y, Ishikawa H.
Jpn J Med. 1987 Feb;26(1):50-7. doi: 10.2169/internalmedicine1962.26.50.
The cyclin-dependent kinase inhibitor p21 limits murine mesangial proliferative glomerulonephritis.
Monkawa T, Pippin J, Yo Y, Kopp JB, Alpers CE, Shankland SJ.
Nephron Exp Nephrol. 2006;102(1):e8-18. doi: 10.1159/000088311. Epub 2005 Sep 19.
Expression and clinical significance of thrombospondin-1 and plasminogen activator inhibitor-1 in patients with mesangial proliferative glomerulonephritis.
Pan C, Zhou C, Shan A, Chen N.
Ann Palliat Med. 2020 Sep;9(5):3187-3193. doi: 10.21037/apm-20-1291. Epub 2020 Aug 31.
Pathological regression by angiotensin II type 1 receptor blockade in patients with mesangial proliferative glomerulonephritis.
Ohtake T, Oka M, Maesato K, Mano T, Ikee R, Moriya H, Kobayashi S.
Hypertens Res. 2008 Mar;31(3):387-94. doi: 10.1291/hypres.31.387.
Non-IgA mesangial proliferative glomerulonephritis. Clinical and pathological analysis of 77 cases.
Chen YP, Wang HY, Zou WZ.
Chin Med J (Engl). 1989 Jul;102(7):510-5.
[Rapidly progressive proliferative glomerulonephritis with monoclonal immunoglobulin G deposits despite the mild histological changes. Case report].
Bajcsi D, Constantinou K, Krenács L, Barabás Z, Molnár S, Nyiraty S, Ábrahám G, Iványi B.
Orv Hetil. 2018 Sep;159(38):1567-1572. doi: 10.1556/650.2018.31072.
Mesangial proliferative glomerulonephritis with irregular intramembranous deposits. Another variant of hypocoplementemic nephritis.
Davis AE, Schneeberger EE, McCluskey RT, Grupe WE.
Am J Med. 1977 Sep;63(3):481-7. doi: 10.1016/0002-9343(77)90289-3.
Patient with diffuse mesangial and endocapillary proliferative glomerulonephritis with hypocomplementemia and elevated anti-streptolysin O treated with prednisolone, angiotensin-converting enzyme inhibitor, and angiotensin II receptor antagonist.
Ito S, Kuriyama H, Iino N, Iguchi S, Shimada H, Ueno M, Narita I, Nakano M, Nishi S, Karasawa R, Gejyo F.
Clin Exp Nephrol. 2003 Dec;7(4):290-5. doi: 10.1007/s10157-003-0244-0.
